DC GLOBAL VENTURES
DC GLOBAL VENTURES is a Seed, Series A, Series B, Series C+ and other fund in Global investing in Healthcare, life-sciences and biotechnology.
- Stages
- Seed, Series A, Series B, Series C+, other
- Sectors
- Healthcare, life-sciences, biotechnology
- Invests in
- Global
- Round role
- Leads rounds
- Actively investing
- Yes
- Founded
- 2012
- Assets under management
- $2.73B
- Website
- decheng.com
Check size not disclosed
Thesis
DC Global Ventures, also known as Decheng Capital, is a venture capital firm founded in 2012 with a global presence and offices in Silicon Valley, Shanghai, and New York. As of December 31, 2025, the firm managed approximately $2.73 billion in AUM. Their primary focus is on the life sciences and healthcare industries, investing in companies with revolutionary technologies. While historically a venture-focused investor in early-stage life science and growth-stage healthcare companies, DC Global Ventures has evolved to become a stage-agnostic investor, supporting companies from incubation to publicly-traded issuers. They invest through pooled investment vehicles like the Decheng Capital China Life Sciences USD Fund I–III, Decheng Capital Global Life Sciences Fund IV, and Decheng Capital Global Healthcare Fund. The firm has acted as a co-investor in Series D rounds for Cellares and as a lead investor in a Series C round for Polares Medical. They also invested in Solve Therapeutics' Series C round, which raised $120 million for ADC development. DC Global Ventures operates as a boutique manager focusing on pooled investment vehicles with venture and hedge fund strategies, registered with the SEC as an investment adviser since 2020.
Common questions
Does DC GLOBAL VENTURES invest at the Seed stage?
Yes. DC GLOBAL VENTURES lists Seed, Series A, Series B, Series C+ and other among the stages it invests in.
Where does DC GLOBAL VENTURES invest?
DC GLOBAL VENTURES invests in Global.